A randomised phase II study of two dose schedules of PI-88 in combination with docetaxel in patients with androgen-independent prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Muparfostat (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ProPIT
- Sponsors Progen Pharmaceuticals Limited
- 10 Jun 2017 Biomarkers information updated
- 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History